Bionik Laboratories Corp. (OTCMKTS:BNKL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On July 22, 2017, the Board of Directors (the “Board”) of Bionik Laboratories Corp. (the “Company”), appointed Dr. Eric Michel Dusseux as a director of the Company, to fill the seat vacated by Hermano Igo Krebs.

Dr. Dusseux, age 49, has been the President Europe and a director at Auregen BioTherapeutics SA, which is translating 3D bioprinting technology for innovative treatments for patients with rare disorders, since February 2017. Prior to that, from November 2016 through January 2017, Dr. Dusseux was President Europe at Bemido SA, a family office. From September 2012 to October 2016, Dr. Dusseux was an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur SA, the vaccines division of Sanofi, a global healthcare leader, where he led corporate strategy, business intelligence, and international business development. He has also served in key roles at GlaxoSmithKline Biologicals from January 2008 to June 2012, leading product development and business growth strategy.

The Company believes that Dr. Dusseux is qualified as a board member of the Company because of his substantial strategic and leadership experience within the healthcare industry.

A copy of the press release announcing Dr. Dusseux’s appointment to the Board is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Bionik Laboratories Corp. Exhibit
EX-99.1 2 v471549_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1       Bionik Laboratories Corp. Names Dr. Eric Dusseux to Board of Directors   Dr. Dusseux brings substantial strategic leadership experience within the healthcare industry to new role at Bionik Laboratories; will work with Board and leadership team to continue Company’s penetration within high-growth potential verticals   TORONTO and BOSTON,…
To view the full exhibit click here

About Bionik Laboratories Corp. (OTCMKTS:BNKL)

Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., is a medical device and robotics company. The Company is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Company is also engaged in developing a lower-body exoskeleton, ARKE, which designs to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking.